JP2024546950A5 - - Google Patents
Info
- Publication number
- JP2024546950A5 JP2024546950A5 JP2024535950A JP2024535950A JP2024546950A5 JP 2024546950 A5 JP2024546950 A5 JP 2024546950A5 JP 2024535950 A JP2024535950 A JP 2024535950A JP 2024535950 A JP2024535950 A JP 2024535950A JP 2024546950 A5 JP2024546950 A5 JP 2024546950A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163290384P | 2021-12-16 | 2021-12-16 | |
| US63/290,384 | 2021-12-16 | ||
| PCT/US2022/081714 WO2023114944A1 (en) | 2021-12-16 | 2022-12-15 | Fluorinated cationic lipids for use in lipid nanoparticles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024546950A JP2024546950A (ja) | 2024-12-26 |
| JP2024546950A5 true JP2024546950A5 (https=) | 2025-12-12 |
| JPWO2023114944A5 JPWO2023114944A5 (https=) | 2025-12-12 |
Family
ID=85108851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535950A Pending JP2024546950A (ja) | 2021-12-16 | 2022-12-15 | 脂質ナノ粒子に用いるフッ化カチオン性脂質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250092002A1 (https=) |
| EP (2) | EP4700017A2 (https=) |
| JP (1) | JP2024546950A (https=) |
| KR (1) | KR20240124983A (https=) |
| CN (1) | CN118647601A (https=) |
| CA (1) | CA3242406A1 (https=) |
| DK (1) | DK4448486T3 (https=) |
| ES (1) | ES3058144T3 (https=) |
| FI (1) | FI4448486T3 (https=) |
| IL (1) | IL313487A (https=) |
| WO (1) | WO2023114944A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250161227A1 (en) | 2023-11-17 | 2025-05-22 | Acuitas Therapeutics, Inc. | Pegylated lipids |
| WO2025128696A1 (en) | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025132122A1 (en) | 2023-12-13 | 2025-06-26 | Berlin Institute Of Health | Methods of delivering therapeutics using lipid nanoparticles |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025166323A2 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | Crispr-related methods and compositions targeting lipoprotein (a) expression |
| WO2025174858A1 (en) | 2024-02-15 | 2025-08-21 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| TW202543583A (zh) | 2024-03-01 | 2025-11-16 | 加拿大商阿奎特斯醫療公司 | 用於將治療劑包覆於脂質奈米顆粒中之材料及方法 |
| WO2025186725A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Improved lnp formulations and uses thereof |
| WO2025189064A1 (en) | 2024-03-08 | 2025-09-12 | Genzyme Corporation | Lipid nanoparticles |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
| TW202602839A (zh) | 2024-04-10 | 2026-01-16 | 加拿大商阿奎特斯醫療公司 | 用於脂質奈米顆粒之陽離子脂質化合物 |
| WO2025231114A1 (en) | 2024-05-01 | 2025-11-06 | Acuitas Therapeutics, Inc. | Method of using lipid nanoparticles for intramuscular delivery |
| WO2025240833A1 (en) | 2024-05-17 | 2025-11-20 | Acuitas Therapeutics, Inc. | Galnac lipid compounds for use in lipid nanoparticles |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197553B1 (en) | 1994-07-15 | 2001-03-06 | Merck & Co., Inc. | Method for large scale plasmid purification |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| US9005654B2 (en) | 2005-07-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| LT3313829T (lt) * | 2015-06-29 | 2024-08-12 | Acuitas Therapeutics Inc. | Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui |
| EP3668834B1 (en) * | 2017-08-17 | 2024-10-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US20200093936A1 (en) * | 2018-09-21 | 2020-03-26 | The Trustees Of The University Of Pennsylvania | Therapeutic Targeting of Lipid Nanoparticles |
-
2022
- 2022-12-15 US US18/720,478 patent/US20250092002A1/en active Pending
- 2022-12-15 IL IL313487A patent/IL313487A/en unknown
- 2022-12-15 FI FIEP22847699.0T patent/FI4448486T3/fi active
- 2022-12-15 EP EP25208298.7A patent/EP4700017A2/en active Pending
- 2022-12-15 CN CN202280090897.4A patent/CN118647601A/zh active Pending
- 2022-12-15 CA CA3242406A patent/CA3242406A1/en active Pending
- 2022-12-15 WO PCT/US2022/081714 patent/WO2023114944A1/en not_active Ceased
- 2022-12-15 EP EP22847699.0A patent/EP4448486B1/en active Active
- 2022-12-15 KR KR1020247023733A patent/KR20240124983A/ko active Pending
- 2022-12-15 ES ES22847699T patent/ES3058144T3/es active Active
- 2022-12-15 DK DK22847699.0T patent/DK4448486T3/da active
- 2022-12-15 JP JP2024535950A patent/JP2024546950A/ja active Pending